Gene Target Prioritization for Obesity Therapy Research

The project covered data ingestion, machine learning model development, target scoring, and deployment of interactive analytics dashboards.The platform was designed to integrate directly into the client’s R&D workflows and support scalable use across additional metabolic programs.

The client is a pharmaceutical research company focused on metabolic disorders and obesity therapeutics.Their objective was to prioritize more than 100 candidate genes and identify which targets showed the strongest therapeutic and translational potential before entering preclinical validation.

Researchers faced a growing list of candidate obesity-related genes but lacked an efficient way to compare them systematically.Manual analysis and disconnected evaluation methods slowed down decision-making and created uncertainty around which targets justified further investment.

During implementation, it became clear that existing prioritization workflows relied heavily on fragmented evidence and subjective interpretation.Teams had access to valuable data, but no unified framework to consistently evaluate targets across scientific and commercial dimensions.

Nextigent AI developed the Target Prioritization and Ranking AI Platform to evaluate obesity-related genes through a structured scoring methodology. The system combined genetic association data, biological evidence, literature analysis, and competitive landscape insights into a unified ranking model. Machine learning algorithms quantified biological plausibility, translational feasibility, and market attractiveness for each target. Interactive dashboards enabled researchers to compare candidates, visualize correlations, and trace evidence directly back to supporting studies.

The client plans to expand the framework into additional metabolic and endocrine disease programs.Future enhancements include predictive modeling for therapeutic response and integration with compound discovery workflows.